FDA Reconsiders Gene Therapy for Huntington's Disease After Official's Ouster
The Food and Drug Administration (FDA) has opened a new path toward approval for UniQure's gene therapy, AMT-130, designed to treat Huntington's disease. This reconsideration follows the departure of several Trump administration officials, particularly Vinay Prasad, who had previously rejected the therapy. A former FDA official described the initial rejection as "truly evil." Huntington's disease is an inherited neurological condition for which there are currently no treatments. Early trial data suggested AMT-130 could slow disease progression by up to 75 percent, sparking hope among patients and advocates.
A gene therapy aimed at treating Huntington's disease has gained a renewed opportunity for approval from the Food and Drug Administration (FDA). This development follows the removal of several Trump administration officials, notably Vinay Prasad, whose earlier rejection of the therapy was termed "truly evil" by one former FDA official.
Huntington's disease is an inherited disorder characterized by the gradual breakdown of nerve cells in the brain. The condition typically manifests in middle age, with affected individuals often dying in their 50s and 60s. Currently, there are no approved treatments for Huntington's disease.
UniQure, a gene therapy company, developed AMT-130, a one-time treatment designed to reduce brain levels of the mutant huntingtin protein responsible for the disease. Data from a small, early-stage trial indicated that the drug might slow the disease's progression by as much as 75 percent. The therapy's development has been closely watched by patients and advocates who have expressed hopeful anticipation.
According to Ars Technica, this new pathway for approval emerged after UniQure had another meeting with the FDA following Vinay Prasad's exit.
